

EXPRESS MAIL NO.: EV452772805US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Spadafora et al.	Confirmation No.:	To Be Assigned
Application No.:	To Be Assigned (National Stage of PCT/EP02/14727, filed December 23, 2002)	Art Unit:	To Be Assigned
Filed:	On even date herewith	Examiner:	To Be Assigned
For:	NON-NUCLEOSIDIC INHIBITORS OF REVERSE TRANSCRIPTASE AS ANTAGONISTS OF CELL PROLIFERATION AND INDUCERS OF CELL DIFFERENTIATION	Attorney Docket No.:	11340-005-999

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.56 AND § 1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the U.S. Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the subject application which are or may be material to the patentability of any claim of the application, Attorneys for Applicants respectfully direct the Examiner's attention to references A01 and C01-C07 listed on the attached revised PTO/SB/08 Form entitled "List of References Cited by Applicants." A copy of references A01 and C01-C07 is submitted herewith.

Identification of the listed references is not to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, it is believed that no fee is due in connection herewith. However, should the Patent and Trademark Office determine otherwise, please charge the required fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

Date: June 24, 2004

Adriane M. Antler 32,605
Adriane M. Antler (Reg. No.)
JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

Enclosures

10/500270 Sheet 1 of 1

LIST OF REFERENCES CITED BY APPLICANTS
(Use several sheets if necessary)

ATTY DOCKET NO.

11340-005-999

APPLICATION NO

To Be Assigned
(National Stage of
PCT/EP02/14727, filed
December 23, 2002)

APPLICANT

Spadafora et al.

FILING DATE

On even date herewith

GROUP

To Be Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/S.K./	A01	6,258,839 B1	07/10/01				

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

/S.K./	C01	Ghori A. et al. Telomerase inhibition as a potential new therapy for colorectal cancer. Colorectal Disease. 2000;2(2):106-112.
/S.K./	C02	Grimaudo S. et al. Selective induction of apoptosis in multidrug resistant HL60R cells by the thiazolobenzoimidazole derivative 1-(2,6-difluorophenyl)-1H,3H-thiazolo [3,4-a] benzimidazole (TBZ). Eur J Cancer. 1998 Oct;34(11):1756-63.
/S.K./	C03	Lam S. et al. Hypsin, a novel thermostable ribosome-inactivating protein with antifungal and antiproliferative activities from fruiting bodies of the edible mushroom Hypsizigus marmoreus. Biochem Biophys Res Commun. 2001 Jul 27;285(4):1071-5.
/S.K./	C04	Modest G. et al. HIV and refractory anemia with excess blasts (RAEB). Am J Hematol. 2002 Aug;70(4):318-9.
/S.K./	C05	Murdaca G. et al. Complete remission of AIDS/Kaposi's sarcoma after treatment with a combination of two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor. AIDS. 2002 Jan 25;16(2):304-5.
/S.K./	C06	Shaw A. et al. Kaposi's sarcoma regression following treatment with a triple antiretroviral regimen containing nevirapine. Int J STD AIDS. 1999 Jun;10(6):417-8.
/S.K./	C07	International Search Report for International Application No. PCT/EP02/14727.

EXAMINER /Shobha Kantamneni/

DATE CONSIDERED 06/12/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.